Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

648 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective evaluation of patient-reported anxiety and experiences with adaptive radiation therapy on an MR-linac.
Moreira A, Li W, Berlin A, Carpino-Rocca C, Chung P, Conroy L, Dang J, Dawson LA, Glicksman RM, Hosni A, Keller H, Kong V, Lindsay P, Shessel A, Stanescu T, Taylor E, Winter J, Yan M, Letourneau D, Milosevic M, Velec M. Moreira A, et al. Among authors: berlin a. Tech Innov Patient Support Radiat Oncol. 2024 Feb 27;29:100240. doi: 10.1016/j.tipsro.2024.100240. eCollection 2024 Mar. Tech Innov Patient Support Radiat Oncol. 2024. PMID: 38445180 Free PMC article.
Acute toxicity and health-related quality of life outcomes of localized prostate cancer patients treated with magnetic resonance imaging-guided high-dose-rate brachytherapy: A prospective phase II trial.
Sanmamed N, Adleman J, Berlin A, Borg J, Lao B, Weersink R, Simeonov A, Rink A, Beiki-Ardakani A, Menard C, Chung P, Helou J. Sanmamed N, et al. Among authors: berlin a. Brachytherapy. 2023 Jan-Feb;22(1):58-65. doi: 10.1016/j.brachy.2022.08.015. Epub 2022 Nov 19. Brachytherapy. 2023. PMID: 36414526 Clinical Trial.
Corrigendum: MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer.
Ménard C, Navarro-Domenech I, Liu ZA, Joseph L, Barkati M, Berlin A, Delouya G, Taussky D, Beauchemin MC, Nicolas B, Kadoury S, Rink A, Raman S, Sundaramurthy A, Weersink R, Beliveau-Nadeau D, Helou J, Chung P. Ménard C, et al. Among authors: berlin a. Front Oncol. 2022 Nov 17;12:1084708. doi: 10.3389/fonc.2022.1084708. eCollection 2022. Front Oncol. 2022. PMID: 36465337 Free PMC article.
Long-term oncologic outcomes of low dose-rate brachytherapy compared to hypofractionated external beam radiotherapy for intermediate -risk prostate cancer.
Sanmamed N, Joseph L, Crook J, Craig T, Warde P, Tomasso AD, Chung P, Berlin A, Bayley A, Saibishkumar EP, Glicksman R, Raman S, Catton C, Helou J. Sanmamed N, et al. Among authors: berlin a. Brachytherapy. 2023 Mar-Apr;22(2):188-194. doi: 10.1016/j.brachy.2022.09.159. Epub 2022 Dec 20. Brachytherapy. 2023. PMID: 36549968
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
Zlotta AR, Ballas LK, Niemierko A, Lajkosz K, Kuk C, Miranda G, Drumm M, Mari A, Thio E, Fleshner NE, Kulkarni GS, Jewett MAS, Bristow RG, Catton C, Berlin A, Sridhar SS, Schuckman A, Feldman AS, Wszolek M, Dahl DM, Lee RJ, Saylor PJ, Michaelson MD, Miyamoto DT, Zietman A, Shipley W, Chung P, Daneshmand S, Efstathiou JA. Zlotta AR, et al. Among authors: berlin a. Lancet Oncol. 2023 Jun;24(6):669-681. doi: 10.1016/S1470-2045(23)00170-5. Epub 2023 May 12. Lancet Oncol. 2023. PMID: 37187202
Practice-based training strategy for therapist-driven prostate MR-Linac adaptive radiotherapy.
Li W, Padayachee J, Navarro I, Winter J, Dang J, Raman S, Kong V, Berlin A, Catton C, Glicksman R, Malkov V, McPartlin A, Kataki K, Lindsay P, Chung P. Li W, et al. Among authors: berlin a. Tech Innov Patient Support Radiat Oncol. 2023 May 13;27:100212. doi: 10.1016/j.tipsro.2023.100212. eCollection 2023 Sep. Tech Innov Patient Support Radiat Oncol. 2023. PMID: 37265510 Free PMC article.
Primary Bladder Sarcoma: A multi-institutional experience from the Rare Cancer Network.
Bettoli P, Liu Z, Jara N, Bakal F, Wong W, Terlizzi M, Sargos P, Zilli T, Thariat J, Sole S, Ploussard G, Goyal S, Chung P, Berlin A, Sole C. Bettoli P, et al. Among authors: berlin a. Arch Ital Urol Androl. 2023 Jul 25;95(3):11533. doi: 10.4081/aiua.2023.11533. Arch Ital Urol Androl. 2023. PMID: 37491942 Free article.
648 results